Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.
about
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@ast
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@en
type
label
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@ast
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@en
prefLabel
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@ast
Feasibility and advantage of a ...... d stage neuroendocrine tumors.
@en
P2093
P2860
P50
P1433
P1476
Feasibility and advantage of a ...... ed stage neuroendocrine tumors
@en
P2093
Mark T Madsen
Randi Ryan
Saima Muzahir
Thomas O'cdorisio
P2860
P2888
P356
10.1186/S13550-014-0038-2
P577
2014-09-10T00:00:00Z
P5875
P6179
1025279980